222 related articles for article (PubMed ID: 23515389)
21. Promoting functional foods and nutraceuticals on the Internet.
Taylor SE; Feld HJ
Food Drug Law J; 1999; 54(3):423-51. PubMed ID: 11797707
[No Abstract] [Full Text] [Related]
22. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
23. Pharmaceuticals and medical devices: business practices. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840
[No Abstract] [Full Text] [Related]
24. FDA oversight of cell therapy clinical trials.
Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
[TBL] [Abstract][Full Text] [Related]
25. Marketing health care products on the Internet: a proposal for updated federal regulations.
Green K
Am J Law Med; 1998; 24(2-3):365-86. PubMed ID: 9702278
[No Abstract] [Full Text] [Related]
26. The new drug marketing: a consumer protection perspective.
Woodward D
Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
[No Abstract] [Full Text] [Related]
27. Regulating drug promotion on the Internet.
Bannon L
Food Drug Law J; 1999; 54(4):599-621. PubMed ID: 11824457
[No Abstract] [Full Text] [Related]
28. When Does FDAMA Section 114 Apply? Ten Case Studies.
Neumann PJ; Saret CJ
Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
[TBL] [Abstract][Full Text] [Related]
29. The FDA Safety and Innovation Act.
Steinbrook R; Sharfstein JM
JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356
[No Abstract] [Full Text] [Related]
30. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
[No Abstract] [Full Text] [Related]
31. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
Mahinka SP; Sanzo KM
Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
[No Abstract] [Full Text] [Related]
32. The dangers of unregulated stem-cell marketing.
Mohammadi D
Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714
[No Abstract] [Full Text] [Related]
33. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
34. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
35. [The advertising of medicinal products to the public in Poland--legislative, ethical, health and social concerns].
Cianciara D
Przegl Epidemiol; 2004; 58(3):555-63. PubMed ID: 15730020
[TBL] [Abstract][Full Text] [Related]
36. The need for FDA regulation of tobacco products.
Kennedy EM
Yale J Health Policy Law Ethics; 2002; 3(1):101-8. PubMed ID: 12825428
[No Abstract] [Full Text] [Related]
37. Regulating direct-to-consumer genetic testing: protecting the consumer without quashing a medical revolution.
Gniady JA
Fordham Law Rev; 2008 Apr; 76(5):2429-75. PubMed ID: 18546580
[No Abstract] [Full Text] [Related]
38. The First Amendment and the Food and Drug Administration's regulation of labeling and advertising: three proposed reforms.
Kahan JS; Shapiro JK
Food Drug Law J; 2003; 58(3):353-64. PubMed ID: 14626983
[No Abstract] [Full Text] [Related]
39. [Legal aspects of selling medical products by gynecologists].
Urbaniak M; Spaczyński RZ
Ginekol Pol; 2013 Jul; 84(7):637-40. PubMed ID: 24032277
[TBL] [Abstract][Full Text] [Related]
40. Globalization of biotechnology and the public health challenges accompanying it.
Malinowski MJ
Albany Law Rev; 1996; 60(1):119-69. PubMed ID: 10170488
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
